Media coverage about Mediwound (NASDAQ:MDWD) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mediwound earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.5001862747948 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Mediwound (NASDAQ:MDWD) opened at $4.15 on Tuesday. The stock has a market cap of $113.60, a price-to-earnings ratio of -4.23 and a beta of 0.01. Mediwound has a fifty-two week low of $3.56 and a fifty-two week high of $8.25.
Mediwound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, November 16th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.74 million. Mediwound had a negative net margin of 904.26% and a negative return on equity of 246.58%. equities analysts expect that Mediwound will post -1.06 EPS for the current fiscal year.
Several analysts have issued reports on the stock. Oppenheimer set a $10.00 target price on shares of Mediwound and gave the company a “buy” rating in a research note on Thursday, November 16th. Zacks Investment Research cut shares of Mediwound from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. ValuEngine upgraded shares of Mediwound from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Finally, SunTrust Banks set a $9.00 price target on shares of Mediwound and gave the company a “buy” rating in a report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.13.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Mediwound (MDWD) Share Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/mediwound-mdwd-getting-somewhat-favorable-media-coverage-report-finds.html.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.